Molecular subtype-specific therapeutic strategies show particular promise in core-binding factor AML (CBF-AML), which is characterized by frequent co-occurring mutations in FLT3, c-KIT, RAS, and other genes that confer adverse prognosis [10]. The gene discussed is FLT3; the disease is acute myeloid leukemia.